Stay updated with breaking news from Jacobio Pharma. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
BEIJING and SHANGHAI and CHICAGO, June 2, 2024 /PRNewswire/ -- Jacobio Pharma (1167.HK), a clinical-stage oncology company focusing on undruggable targets,
/PRNewswire/ -- Jacobio Pharma (1167.HK), a clinical-stage oncology company focusing on undruggable targets, presented updated data of a KRAS G12C inhibitor...
/PRNewswire/ -- Jacobio Pharma (1167.HK) announced that the data from the Phase II registrational study of the KRAS G12C inhibitor glecirasib were offically...
/PRNewswire/ -- Jacobio Pharmaceuticals (1167.HK), a clinical-stage oncology company focusing on undruggable targets, announced data of glecirasib in patients...
/PRNewswire/ -- Jacobio Pharma (1167.HK), a clinical-stage oncology company focusing on undruggable targets, is pleased to announce today that the company will...